Also known as: Relay Therapeutics
Relay Therapeutics is a clinical-stage precision medicines company focused on transforming small-molecule drug discovery for targeted oncology and genetic diseases. Its pipeline includes RLY-2608 and other candidates developed through protein-motion-based computational approaches.
Relay Therapeutics reported full-year 2025 revenue of $15.36 million and a narrowed net loss of $276.48 million, while securing FDA Breakthrough Therapy designation for lead asset zovegalisib. The company filed a $96.18 million shelf registration.
MoonLake Immunotherapeutics says FDA feedback indicates sufficient data to support a U.S. BLA for hidradenitis suppurativa without additional efficacy trials, while Relay Therapeutics received FDA Breakthrough Therapy designation for zovegalisib in combination with fulvestrant for PIK3CA-mutant breast cancer.
